Media stories about BioDelivery Sciences International (NASDAQ:BDSI) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.7035078694957 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Shares of BioDelivery Sciences International (BDSI) opened at $2.63 on Friday. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a 52 week low of $1.55 and a 52 week high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The business had revenue of $11.25 million during the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. BioDelivery Sciences International’s revenue for the quarter was up 215.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. equities analysts predict that BioDelivery Sciences International will post 0.16 EPS for the current fiscal year.

Several equities research analysts have recently weighed in on the company. ValuEngine cut BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald restated an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. HC Wainwright assumed coverage on shares of BioDelivery Sciences International in a research report on Sunday, September 10th. They issued a “buy” rating and a $5.00 price objective on the stock. Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Finally, Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $4.29.

In other news, insider Mark A. Sirgo sold 201,373 shares of the stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $2.84, for a total transaction of $571,899.32. Following the completion of the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at $4,286,304.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Mark A. Sirgo sold 24,516 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.75, for a total value of $67,419.00. Following the sale, the chief executive officer now directly owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 297,294 shares of company stock valued at $836,282. 9.00% of the stock is owned by insiders.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/biodelivery-sciences-international-bdsi-earning-somewhat-positive-media-coverage-analysis-shows/1764976.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.